On February 18, 2024, Jennifer Lew, the Chief Financial Officer of Annexon, Inc. (NASDAQ: ANNX), executed the sale of 7,851 shares of the company’s stock at an average price of $5.11. This transaction resulted in a total value of approximately $40,118.61. Following this sale, Lew retained 113,765 shares, valued at about $581,339.15, marking a 6.46% reduction in her ownership.
The sale was reported in a legal filing with the Securities and Exchange Commission (SEC), which is publicly accessible for further details. In the wake of this news, Annexon’s stock experienced a decline, trading down by 3.9% on February 23, 2024, to reach $4.90. The trading volume for that day was 1,749,100 shares, slightly below its average volume of 1,986,881 shares.
Market Overview and Insider Activity
As of the latest reports, Annexon holds a market capitalization of approximately $586.19 million. The company has a price-to-earnings (P/E) ratio of -3.48 and a beta of 1.17, indicating higher volatility compared to the market. The stock has fluctuated significantly over the past year, with a low of $1.28 and a high of $7.18. Currently, the 50-day moving average price stands at $5.58, while the 200-day moving average price is $3.94.
This week, several other executives have also sold shares, indicating a trend of insider trading activity. Notably, Michael Overdorf, Executive Vice President, sold 6,225 shares at an average price of $5.10, reflecting a decline of approximately 4.8% in his holdings. Similarly, Ted Yednock and Dean Richard Artis sold 7,857 shares and 5,290 shares, respectively, each at similar average prices, contributing to a negative sentiment among investors.
Institutional Activity and Company Profile
In recent quarters, institutional investors have actively adjusted their positions in Annexon. Wealth Enhancement Advisory Services LLC increased its stake by 13.6% during the fourth quarter, now holding 19,553 shares valued at $100,000. Another significant move came from Mirae Asset Global Investments Co., Ltd., which raised its stake by 65.6%, acquiring 7,033 shares valued at $35,000.
Annexon Inc. is a clinical-stage biotechnology company dedicated to developing complement-targeted therapies for neurodegenerative and neuroimmune diseases. Its primary research focuses on inhibiting the C1 complex, a critical initiator in the classical complement pathway, which plays a significant role in various rare and life-threatening conditions. The company’s flagship product, ANX005, is currently undergoing Phase 2 clinical trials aimed at conditions like Guillain-Barré syndrome and other chronic neurodegenerative disorders.
As the market continues to react to these developments, stakeholders will be closely monitoring further insider trading activity and institutional investments, which can significantly influence Annexon’s stock performance and overall market perception.
